<DOC>
	<DOC>NCT01034579</DOC>
	<brief_summary>This study, REbif® vs Glatiramer acetate in relapsing multiple sclerosis (MS) disease - pharmacogenetic(s) (REGARD-PGx) is a single blood sampling exploratory pharmacogenetic study of the REGARD trial. The aim of this trial is to provide additional data on the factors influencing interferon (IFN) beta response. This is a Phase 4 trial involving subjects who previously participated in the REGARD trial. To address the trial objectives, a single visit follow-up trial will be performed during which a blood sample will be collected.</brief_summary>
	<brief_title>The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Was randomized in the REGARD 24735 study Is willing and able to comply with the protocol Has given written informed consent before performing any trialrelated activities Is unwilling or unable to participate in the study Is already included in the initial REGARD 24735 PGx substudy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Biomarkers</keyword>
	<keyword>Genetic markers</keyword>
</DOC>